NXTC earnings: next report 2026-08-06, real EPS beat/miss history, analyst consensus Buy, P/E -0.23. Updated 2026-07-23.
NextCure (NXTC) Research Hub
NextCure (NXTC) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 7 USD (-13.26%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.23, market cap 0.01B. This hub links to the full technical, earnings and options research available for NXTC.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 7 USD (-13.26%) |
| 52-week range | 1.55 USD – 8.66 USD |
| Trend regime | Range |
| 14-day RSI | 56.5 (Bullish) |
| Trailing P/E | -0.23 |
| Market cap | 0.01B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-06 |
Available research for NXTC
Covered Call on NXTC: how it works, illustrative setup around the real 7 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on NXTC: how it works, illustrative setup around the real 7 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on NXTC: how it works, illustrative setup around the real 7 USD price, max profit/loss, breakeven and when to use it. Educational.
NXTC technical analysis: range, last 7 USD, RSI 56.5, 52w range 1.55 USD–8.66 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is NXTC in?
NextCure (NXTC) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is NXTC in an uptrend or downtrend?
As of 2026-09-11, NXTC is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is NXTC's trailing P/E ratio?
NXTC's trailing P/E is -0.23, with a market cap of 0.01B. See the earnings research page for full valuation detail.
When does NXTC next report earnings?
NXTC is next scheduled to report earnings on 2026-08-06, with a consensus EPS estimate of -1.98 USD.